- Home
- SIFY vs ALT Comparison
SIFY vs ALT Comparison
Compare SIFY & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIFY
- ALT
- Stock Information
- Founded
- SIFY 1995
- ALT 1997
- Country
- SIFY India
- ALT United States
- Employees
- SIFY N/A
- ALT N/A
- Industry
- SIFY Computer Software: Programming Data Processing
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- SIFY Technology
- ALT Health Care
- Exchange
- SIFY Nasdaq
- ALT Nasdaq
- Market Cap
- SIFY 369.1M
- ALT 339.0M
- IPO Year
- SIFY 1999
- ALT N/A
- Fundamental
- Price
- SIFY $5.55
- ALT $4.08
- Analyst Decision
- SIFY
- ALT Strong Buy
- Analyst Count
- SIFY 0
- ALT 6
- Target Price
- SIFY N/A
- ALT $18.20
- AVG Volume (30 Days)
- SIFY 72.7K
- ALT 6.6M
- Earning Date
- SIFY 07-18-2025
- ALT 08-07-2025
- Dividend Yield
- SIFY N/A
- ALT N/A
- EPS Growth
- SIFY N/A
- ALT N/A
- EPS
- SIFY N/A
- ALT N/A
- Revenue
- SIFY $480,237,627.00
- ALT $20,000.00
- Revenue This Year
- SIFY N/A
- ALT N/A
- Revenue Next Year
- SIFY $13.46
- ALT $507,435.66
- P/E Ratio
- SIFY N/A
- ALT N/A
- Revenue Growth
- SIFY 12.82
- ALT N/A
- 52 Week Low
- SIFY $1.84
- ALT $2.90
- 52 Week High
- SIFY $5.95
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- SIFY 62.11
- ALT 40.20
- Support Level
- SIFY $4.84
- ALT $4.03
- Resistance Level
- SIFY $5.95
- ALT $4.39
- Average True Range (ATR)
- SIFY 0.36
- ALT 0.23
- MACD
- SIFY 0.06
- ALT 0.03
- Stochastic Oscillator
- SIFY 71.43
- ALT 18.43
About SIFY Sify Technologies Limited
Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.